Unassociated Document
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending October 2014
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 6 October 2014, of changes in the interests of the following Directors and Persons Discharging Managerial Responsibility, following increases in their notional interests in Ordinary Shares and American Depositary Shares (ADSs), at a price of 1414.00 pence per Ordinary Share and $45.90 per ADS, following the re-investment of dividends paid on Ordinary Shares and ADSs held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
|
Director/PDMR
|
Number of Ordinary Shares acquired under
the personal contribution element of the plan
|
Number of Ordinary Shares acquired under the matching element of the plan
(GSK contribution)
|
|
Sir Andrew Witty
|
1,994
|
1,994
|
|
Mr S Dingemans
|
877
|
877
|
|
Mr S M Bicknell
|
199
|
199
|
|
Mr R G Connor
|
224
|
224
|
|
Mr S A Hussain
|
113
|
113
|
|
Mr D S Redfern
|
426
|
426
|
|
Ms C Thomas
|
322
|
322
|
|
Mr P C Thomson
|
65
|
65
|
|
Dr P J T Vallance
|
935
|
935
|
|
Ms E Walmsley
|
516
|
516
|
|
Director/PDMR
|
Number of ADSs acquired under the personal contribution element of the plan
|
Number of ADSs acquired under the matching element of the plan
(GSK contribution)
|
|
Dr M M Slaoui
|
816
|
816
|
|
Mrs D P Connelly
|
157
|
157
|
|
Mr W C Louv
|
197
|
197
|
|
Mr D E Troy
|
361
|
361
|
The notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that will vest following the end of the relevant measurement period.
V A Whyte
Company Secretary
6 October 2014
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: October 06, 2014
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc